All Title Author
Keywords Abstract

-  2016 

复方丹参滴丸对大鼠糖尿病肾病早期的肾脏保护及作用机制
Protective effects of Compound Danshen Dripping Pills on early diabetic kidney disease and its underlying mechanism

DOI: 10.7652/jdyxb201601025

Keywords: 复方丹参滴丸,糖尿病肾病,尿白蛋白排泄率,血管内皮生长因子,结缔组织生长因子,巨噬细胞趋化蛋白-1
Compound Danshen Dripping Pill
,diabetic kidney disease,urinary albumin excretion rate,VEGF,CTGF,MCP-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

摘要:目的 探讨复方丹参滴丸对早期糖尿病肾病的保护作用及可能机制。方法 腹腔注射链脲佐菌素建立高血糖大鼠动物模型。造模成功的大鼠随机分为模型组、复方丹参组以及厄贝沙坦组,分别给予蒸馏水、复方丹参滴丸及厄贝沙坦灌胃。另设正常对照组以同体积蒸馏水灌胃。测定尿白蛋白、血肌酐及血糖;肾脏组织行PAS、Masson染色,电镜观察超微结构,免疫组化检测肾组织血管内皮生长因子(VEGF)、结缔组织生长因子(CTGF)、巨噬细胞趋化蛋白-1(MCP-1)的表达。结果 复方丹参滴丸大剂量时可减少尿白蛋白排泄率、减轻肾脏的病理变化。降低肾小球VEGF、CTGF、MCP-1蛋白表达水平。结论 复方丹参滴丸能有效改善糖尿病所致的肾脏损害,其保护作用可能与降低生长因子和炎症因子有关。
ABSTRACT: Objective To explore the effects of Compound Danshen Dripping Pills (CDDP) on early diabetic kidney disease in streptozocin-induced rats of hyperglycemia, and its underlying mechanism. Methods Hyperglycemic rat animal model was established by intraperitoneal injection of streptozotocin. The model rats were then randomly divided into model group, Compound Danshen Dripping group and irbesartan group. They were then given distilled water, compound Danshen Dripping Pills and irbesartan by intragastric administration, respectively. An additional control group received the same volume of distilled water instead. Urinary albumin, serum creatinine and blood glucose were determined; kidney tissues were observed by PAS and Masson staining; the renal ultrastructures were assessed by electron microscopy. The VEGF, CTGF, and MCP-1 expressions were immunohistochemically detected. Results Compound Danshen Dripping Pills in large doses reduced blood sugar and urinary albumin excretion rate. The renal pathological changes were ameliorated by Compound Danshen Dripping pills. VEGF, CTGF, MCP-1 protein expression levels were decreased. Conclusion Compound Danshen Dripping Pills can effectively reduce renal damage caused by diabetes, which may be related to the decreased expressions of VEGF and inflammatory factors

References

[1]  邹万忠. 糖尿病肾病的病理与分型[J]. 中国糖尿病杂志, 2009, 17(6):423-425.
[2]  张静,吴靖芳,郑慧娥,等. 链脲佐菌素致大鼠糖尿病模型的实验研究[J]. 河北北方学院学报, 2006, 23(4):6-8.
[3]  张冬梅,魏素文,段好刚,等. 链脲佐菌素诱导制备糖尿病大鼠模型方法学考察[J]. 兰州大学学报(医学版), 2008, 34(3):17-19.
[4]  ANAVEKAR NS, GANS DJ, BERL T, et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria[J]. Kidney Int Suppl, 2004, 66(92):S50-S55.
[5]  KARALLIEDDE J, VIBERTI G. Hypertension and microalbuminuria: risk factors for cardiovascular disease in diabetes[J]. Curr Hypertens Rep, 2005, 7(1):1-2.
[6]  周小军,李良,周玲娟,等. 复方丹参滴丸对2型糖尿病肾病患者微量蛋白尿的疗效[J]. 中国新药杂志, 2009, 18(15):1427-1429.
[7]  ADVANI A. Vascular endothelial growth factor and the kidney: something of the marvellous[J]. Curr Opin Nephrol Hypertens, 2014, 23(1):87-92.
[8]  冯敏,徐成波,温俊平,等. 糖基化终产物对人肾小球系膜细胞氧化应激及MCP-1表达的影响及机制[J]. 中国应用生理学杂志, 2014, 30(4):306-310.
[9]  YANG W, LU J, WENG J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[10]  TUFRO A, VERON D. VEGF and podocytes in diabetic nephropathy[J]. Semin Nephrol, 2012, 32(4):385-393.
[11]  张席军,安文军. 中期因子及CTGF与糖尿病肾病患者纤维化相关因子关系探讨[J]. 昆明医科大学学报, 2015, 36(4):61-63.
[12]  FIORETTO P, MAUER M. Histopathology of diabetic nephropathy[J]. Semin Nephrol, 2007, 27(2):195-207.
[13]  JIAO B, WANG YS, CHENG YN, et al. Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-beta1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels[J]. Biosci Trends, 2011, 5(4):173-181.
[14]  刘海燕,陈孝文,刘华锋,等. 三七总甙对尿毒血清诱导的HK-2细胞增殖及总胶原分泌的影响[J]. 中国中西医结合肾病杂志, 2004, 5(3):143-145.
[15]  刘海燕,陈孝文,刘华锋,等. 三七总苷对尿毒血清诱导的人肾小管上皮细胞TGF-β1、CTGF基因表达和蛋白分泌的影响[J]. 中国药理学通报, 2005, 21(11):1366-1370.
[16]  MASON RM, WAHAB NA. Extracellular matrix metabolism in diabetic nephropathy[J]. J Am Soc Nephrol, 2003, 14(5):1358-1373.

Full-Text

comments powered by Disqus